Idexx Laboratories, Inc [IDXX] stock is trading at $658.06, up 1.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The IDXX shares have gain 22.88% over the last week, with a monthly amount glided 21.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on August 05, 2025, when BTIG Research reiterated its Buy rating and also boosted its price target to $785 from $545. Previously, Jefferies started tracking the stock with Buy rating on July 01, 2025, and set its price target to $625. On December 02, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $500 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $580 on July 25, 2024. Piper Sandler downgraded its rating to a Neutral but $525 remained the price target by the analyst firm on January 30, 2024. Exane BNP Paribas started tracking with a Outperform rating for this stock on December 07, 2023, and assigned it a price target of $602. In a note dated December 04, 2023, Cleveland Research upgraded an Buy rating on this stock.
Idexx Laboratories, Inc [IDXX] stock has fluctuated between $356.14 and $688.12 over the past year. Currently, Wall Street analysts expect the stock to reach $715.67 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $658.06 at the most recent close of the market. An investor can expect a potential return of 8.75% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 4.04B for the trailing twelve months, which represents a growth of 10.55%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.3%, and Net Profit Margin reading is 0.24%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is 0.64 and Total Capital is 0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.85.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Idexx Laboratories, Inc’s Current Ratio is 1.06. On the other hand, the Quick Ratio is 0.74, and the Cash Ratio is 0.13. Considering the valuation of this stock, the price to sales ratio is 13.04, the price to book ratio is 36.15 and price to earnings (TTM) ratio is 54.77.
Transactions by insiders
Recent insider trading involved Hunt Nimrata, Executive Vice President, that happened on Aug 06 ’25 when 7143.0 shares were sold. President and CEO, MAZELSKY JONATHAN JAY completed a deal on Aug 06 ’25 to sell 29260.0 shares. Meanwhile, Executive Vice President Lane Michael sold 8411.0 shares on Aug 06 ’25.
